Works matching IS 20542577 AND DT 2022 AND VI 9 AND IP 3


Results: 13
    1
    2

    randomized feasibility study evaluating temozolomide circadian medicine in patients with glioma.

    Published in:
    Neuro-Oncology Practice, 2022, v. 9, n. 3, p. 193, doi. 10.1093/nop/npac003
    By:
    • Damato, Anna R;
    • Katumba, Ruth G N;
    • Luo, Jingqin;
    • Atluri, Himachandana;
    • Talcott, Grayson R;
    • Govindan, Ashwin;
    • Slat, Emily A;
    • Weilbaecher, Katherine N;
    • Tao, Yu;
    • Huang, Jiayi;
    • Butt, Omar H;
    • Ansstas, George;
    • Johanns, Tanner M;
    • Chheda, Milan G;
    • Herzog, Erik D;
    • Rubin, Joshua B;
    • Campian, Jian L
    Publication type:
    Article
    3
    4

    Forthcoming Meetings.

    Published in:
    Neuro-Oncology Practice, 2022, v. 9, n. 3, p. 251, doi. 10.1093/nop/npac031
    Publication type:
    Article
    5
    6
    7
    8
    9
    10
    11
    12
    13